Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II dose-finding study of continuous-infusion Alimta in advanced solid tumors
2006-003742-42Phase 2Active
- Sponsor
- Istituto Oncologico Romagnolo
- Start
- Jun 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of pemetrexed in pleural mesothelioma, non-small cell lung cancer (NSCLC), pancreatic cancer (PC) and 1 more (4 arms), sponsored by Istituto Oncologico Romagnolo. Primary endpoints: Maximum tolerated dose and Dose limiting toxicity. Started Jun 2007; status: active.
02
Drugs
pemetrexed
03
Conditions
pleural mesotheliomanon-small cell lung cancer (NSCLC)pancreatic cancer (PC)breast cancer
Beyond the preview
Go deeper on 2006-003742-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-003742-42.